RecallClass 4 · Caution in use

Class 4 Medicines Defect Notification: Star Pharmaceuticals Ltd, Enalapril maleate/ Hydrochlorothiazide 20 mg/12.5 mg Tablets, EL(26)A/48

Issued 12 Nov 2026 · EL(26)A/48 · Star Pharmaceuticals Ltd

Read and act on the official notice on GOV.UK

Print a defect notification check sheet One A4 sheet to work through the shelves and keep as your record.

Class 4 defect notification — Caution in use. The MHRA uses Class 4 when: Usually minor defects in packaging or other printed materials.
What all four recall classes mean
ClassActionThe MHRA's definition
Class 1Immediate actionThe defect presents a risk of death or disability.
Class 2Action within 48 hoursThe defect may cause mistreatment or harm to the patient, but it is not life-threatening or serious.
Class 3Action within 5 daysThe defect is unlikely to cause harm to the patient.
Class 4 this noticeCaution in useUsually minor defects in packaging or other printed materials.

A Class 1 recall usually comes with a National Patient Safety Alert. Source: MHRA, safety communications.

In plain English, for the pharmacy team

Why is this relevant to community pharmacy

This is a blood pressure medicine that also contains a water tablet. The notice says there is a typo on the front of the carton: it prints hydrochlorothiazide as “12 mg” instead of “12.5 mg”. The tablets themselves are not affected, so it matters for pharmacists, dispensers and pharmacy assistants when checking stock and answering patient queries.

What to tell patients

Use your professional judgement for each patient.

  • Continue to take this medicine as prescribed.
  • The tablets are not affected by this labelling error.
  • If you are unsure or have any questions, please seek advice from your pharmacy or other healthcare professionals involved in your treatment.
  • If you have any side effects or concerns about your medicine, seek medical advice.
  • Suspected side effects should be reported via the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme.

What needs to be done

  • Note the Class 4 medicines defect notification for the batches listed in the notice.
  • Continue to dispense this product; the notice says the quality of the tablets is not affected by the labelling defect.
  • Pharmacists: if patients ask, reassure them that this is enalapril maleate 20 mg / hydrochlorothiazide 12.5 mg tablets as described in the Patient Information Leaflet (PIL).
  • If a patient reports a suspected adverse reaction, advise that it should be reported via the MHRA Yellow Card scheme.
  • Read and act on the official GOV.UK notice.

Pharmshark summary, checked and approved by Chris Dotchin on 12 Nov 2026. It is not the official notice: always read and act on the GOV.UK notice.

How this summary was written

An AI tool drafted it from the MHRA's own notice and nothing else. A second check compared every line with the notice. Pharmshark's clinical lead then read it against the notice, edited it where needed and approved it. If the MHRA changes the notice, this summary is taken down until it has been checked again.

The MHRA's summary

Star Pharmaceuticals Limited have informed the MHRA of a typographical error on the strength of hydrochlorothiazide printed on the front face of the carton which incorrectly states “12. mg” instead of “12.5 mg”.

Affected batches

As listed by the MHRA, exactly as published. Always check against the GOV.UK notice before acting.

Batch numberExpiryPack sizeFirst distributed
Enalapril maleate/Hydrochlorothiazide 20 mg/12.5 mg Tablets
Y01819830/06/20272822/09/2026
Y01963531/10/20272805/12/2025
C12548329/02/20282805/03/2026
C13554130/11/20282808/06/2026

Open the official GOV.UK notice

MHRA's audience tags: Dispensing GP practices, Pharmacy

Pharmshark is not an official alerting route. Make sure your pharmacy receives alerts directly from the MHRA and through your organisation, and always act on the official GOV.UK notice.

Source: the MHRA on GOV.UK. Contains public sector information licensed under the Open Government Licence v3.0. Pharmshark is not affiliated with or endorsed by the MHRA.